NCT02307500View on ClinicalTrials.gov

Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2017

Study Completion Date

August 31, 2020

Conditions
Pancreas CancerOvarian CancerMelanomaSarcomaThymoma Type B3Thymoma Type B2Thymic Carcinoma
Interventions
DRUG

Regorafenib

oral therapy

Trial Locations (1)

20089

Istituto Clinico Humanitas, Rozzano

All Listed Sponsors
lead

Istituto Clinico Humanitas

OTHER

NCT02307500 - Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy | Biotech Hunter | Biotech Hunter